A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia

Inclusion Criteria: * patients aged more than 6 months. * the immune phenotype analysis of patients with malignant B cell surface expression CD19 molecules. * the Karnofsky performance status score over 80 points, is expected to patients survival time is more than 3 months. * the important viscera function meet: heart ultrasound tip heart ejection fraction 50% or higher, electrocardiogram (ecg) not seen obvious abnormality;The blood oxygen saturation 90% or higher;Creatinine 2.5 times normal range or less; aspartate aminotransferase and aspartate aminotransferase3 times normal range or less, total bilirubin of 2.0 mg/dl or less. * or greater Hgb 80 g/L. * no contraindications to solid and cell separation * the patient and family to have a strong willingness to participate in clinical trials, and are willing to bear all the consequence caused by the test failed, and sign the informed consent. * the panel discussion, combined with patient general condition, think the benefit is greater than the risks involved in the clinical trials. Exclusion Criteria: * accompanied with other active disease, the treatment is difficult to correct. * bacteria, fungus, or virus infection, unable to control. * people living with HIV. * active hepatitis B virus and hepatitis C virus infection. * of pregnancy and nursing mothers. * before entering the test of the use of glucocorticoid systemic treatment within a week. * confirmed before used CAR - but invalid patients treated T cells, after in the physical examination, experts discuss confirmed by a team doesn't fit in the CAR again - T treatment.Before used gene therapy method. * the researchers believe that might increase risk subjects or interfere with the test results of any situation.